Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Kortüm KM, et al. Among authors: liebisch p. Br J Haematol. 2015 Feb;168(4):507-10. doi: 10.1111/bjh.13171. Epub 2014 Oct 10. Br J Haematol. 2015. PMID: 25302557 Free PMC article.
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Salwender H, Hebart H, Straka C, Knop S. Einsele H, et al. Among authors: liebisch p. Br J Haematol. 2017 Nov;179(4):586-597. doi: 10.1111/bjh.14920. Epub 2017 Sep 29. Br J Haematol. 2017. PMID: 28961309 Free article. Clinical Trial.
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
Straka C, Salwender H, Knop S, Vogel M, Müller J, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Einsele H. Straka C, et al. Among authors: liebisch p. Eur J Haematol. 2021 Nov;107(5):529-542. doi: 10.1111/ejh.13690. Epub 2021 Aug 28. Eur J Haematol. 2021. PMID: 34270825
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,. Kropff M, et al. Among authors: liebisch p. Br J Haematol. 2007 Aug;138(3):330-7. doi: 10.1111/j.1365-2141.2007.06656.x. Br J Haematol. 2007. PMID: 17614819 Free article. Clinical Trial.
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
Straka C, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Fischer T, Liebisch P, Engelhardt M, Einsele H. Straka C, et al. Among authors: liebisch p. Eur J Haematol. 2019 Sep;103(3):255-267. doi: 10.1111/ejh.13281. Epub 2019 Jul 19. Eur J Haematol. 2019. PMID: 31231828 Clinical Trial.
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom. Knop S, et al. Among authors: liebisch p. Leukemia. 2019 Nov;33(11):2710-2719. doi: 10.1038/s41375-019-0537-2. Epub 2019 Aug 28. Leukemia. 2019. PMID: 31462732 Clinical Trial.
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC. Knop S, et al. Among authors: liebisch p. Blood. 2009 Apr 30;113(18):4137-43. doi: 10.1182/blood-2008-10-184135. Epub 2009 Jan 30. Blood. 2009. PMID: 19182205 Free article. Clinical Trial.
Prognostic significance of serum cystatin C in multiple myeloma.
Nückel H, Langer C, Herget-Rosenthal S, Wichert M, Assert R, Döhner H, Dührsen U, Liebisch P. Nückel H, et al. Among authors: liebisch p. Int J Hematol. 2012 May;95(5):545-50. doi: 10.1007/s12185-012-1049-2. Epub 2012 Mar 18. Int J Hematol. 2012. PMID: 22426688
50 results